• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Bye-Bye China?

    Decentralized Trials Fuel AI Revolution in Clinical Research

    Self-Medication: Flexibility for Patients and Drug Manufacturers

    The Single-Use Mixing Landscape: Evaluating Your Options

    DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Civica to Build an Essential Medicines Manufacturing Facility in Virginia

    Humanigen, Emergent Enter Covid-19 Partnership

    Samsung Bioepis Opens New Headquarters

    Pfizer, BioNTech Enter Vax Pact with COVAX

    FDA Approves Janssen’s CABENUVA
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Civica to Build an Essential Medicines Manufacturing Facility in Virginia

    Humanigen, Emergent Enter Covid-19 Partnership

    Samsung Bioepis Opens New Headquarters

    Integrated Continuous Manufacturing ICM

    CONTINUUS Awarded $69.3M DoD Grant
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Civica to Build an Essential Medicines Manufacturing Facility in Virginia

    WDSrx Expands Warehouse Network

    Catalent Acquires Acorda’s INBRIJA Manufacturing Operations

    Varcode, PL Developments Form Strategic ‘Smart Tag’ Pact

    COVID-19 Vaccine Distribution: The Air Cargo Industry’s Greatest Challenge
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Humanigen, Emergent Enter Covid-19 Partnership

    Samsung Bioepis Opens New Headquarters

    Lilly Completes $1B Acquisition of Prevail

    Top BioPharma Form Accumulus Synergy

    Coating Place Wurster Fluid Bed Process Scaling
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Samsung Biologics Adopts Veeva Vault QMS to Unify Quality Management
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Alcami

    Aphena Pharma Solutions

    Baxter BioPharma Solutions

    Emergent BioSolutions

    Syngene
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Cytovance Biologics

    Almac Group

    Syngene

    Reed-Lane

    Alcami
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    CMO/CDMO Sector Mega-Mergers & Acquisitions

    A look at recent M&A activity among contract service providers

    CMO/CDMO Sector  Mega-Mergers & Acquisitions
    Related CONTENT
    • LSNE Expands Fill Finish and Lyophilization Ops
    • Drug Product Development, Manufacturing, and Packaging
    • Irisys Receives NIH Contract for the Formulation of Drinabant
    • AGC Biologics Manufactures Orchard Therapeutics' Libmeldy
    • Ajinomoto Bio-Pharma and Revance Therapeutics Partner
    Kristin Brooks, Contract Pharma11.07.17
    Similar to what the CRO industry experienced in the ten years from 2006-2016, which continues today, mergers and acquisitions have turned their sights on the CMO and CDMO sector. Leading global providers as well as smaller, specialty service providers are the target of acquisition efforts to gain/dominate market share. In line with increased outsourcing within the pharma/biopharma industry, demand for greater capacity, advanced technologies, and global infrastructure, for increasingly complex drug products, namely biologics, has prompted a flurry of M&A within the past nine months.

    Most recently, Catalent acquired Cook Pharmica for approximately $1.7 billion, significantly expanding its position in biologics development and analytical services, manufacturing, and finished product supply, and has since established two new business units for Biologics and Oral Drug Delivery.

    Cook Pharmica operates an 875,000 sq.-ft. development and manufacturing facility in Bloomington, IN with capabilities across biologics development, clinical and commercial cell culture manufacturing, formulation, finished-dose manufacturing, and packaging. For the twelve months ended June 30, 2017, the company generated $179 million in revenue.

    Additionally, 3SBio Inc., a Chinese biopharmaceutical company, through a joint venture formed with CPE Funds, acquired the CDMO business of Canada-based biologics manufacturer Therapure Biopharma for $290 million. With this acquisition, 3SBio enters the North American biopharmaceutical sector, and expands its CDMO business with manufacturing assets that enhance its technical biologics capabilities.

    Therapure provides therapeutic protein development and manufacturing services, including technology transfer and process development, analytical development and testing, scale-up and cGMP manufacturing and aseptic fill/finish and lyophilization.

    In June, Albany Molecular Research was acquired by affiliates of The Carlyle Group and GTCR for $922 million. AMRI, a global contract research and manufacturing organization with locations in North America, Europe and Asia, has business segments including Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), Drug Product (DP), and Fine Chemicals (FC).

    In another major deal, Thermo Fisher Scientific, a leading maker of scientific instruments, acquired Patheon, a contract development and manufacturing organization for $7.2 billion, expanding its capabilities and efforts to become a one-stop shop for drug development and manufacturing services.

    This acquisition leverages Patheon’s network of facilities primarily in North America and Europe, which employs approximately 9,000 professionals worldwide. Earlier this year, Patheon acquired a 300,000 sq.-ft. API manufacturing facility in Florence, SC, from Roche Holdings, expanding its capacity for manufacturing highly potent compounds and adding capabilities to support solid-state chemistry, micronization, and eventually, commercial spray drying. This was Patheon’s sixth acquisition in the last five years to expand pharma development and manufacturing services.

    The company generated revenue of approximately $1.9 billion in 2016 and will become part of Thermo Fisher’s Laboratory Products and Services Segment.

    In December 2016, Lonza acquired Capsugel for $5.5 billion in cash, expanding its market reach and contract development and manufacturing products businesses. The acquisition aims to integrate services in drug development, formulation, delivery technologies and manufacturing for the global pharma and consumer healthcare industries. The combined business will offer active pharmaceutical ingredients (APIs) and excipients to dosage forms and delivery technologies.

    Capsugel brings advanced oral dosage delivery technologies, including its hard capsule technologies, and the combined technologies and offerings will provide services in both large and small molecules. The company has approximately 3,600 employees and 13 facilities on three continents. The combined business would have had combined 2015 revenues of approximately CHF 4.8 billion.

    APIs, Early Development and Beyond
    In the early development arena, several CDMOs have expanded capabilities into later phases of the development and manufacturing process. For example, Evotec acquired Aptuit for $300 million, strengthening its outsourced drug discovery and development services. Aptuit offers services across drug discovery, preclinical testing and both drug substance and drug product manufacturing.

    Aptuit provides early discovery to mid-phase drug development services to the pharma and biopharma industry. It has approximately 750 employees working across three discovery, development and manufacturing facilities in Europe (Verona, Italy; Basel, Switzerland; and Oxford, UK).

    The acquisition substantially expands Evotec’s business and extends its offering through to investigational new drug (IND) submission and beyond to integrated drug substance and drug product and commercial manufacture.

    Moreover, in July, STA Pharmaceutical, a WuXi AppTec group company, merged with WuXi AppTec’s Pharmaceutical Development Services (PDS) division.

    The PDS division offers pre-formulation development, formulation development, as well as clinical trial material (CTM) manufacturing, packaging and labeling of oral solid dosage forms including tablets, capsules, sachets and oral solutions/suspensions. PDS also established various enabling technology platforms for low soluble drugs including spray dried dispersion, hot-melt extrusion, micro or nano suspension and liquid-filled hard gelatin capsules. Two commercial-scale drug product manufacturing facilities currently under construction are expected to become operational later this year and early next year, respectively.

    Following this merger, STA will provide small molecule active pharmaceutical ingredient (API) and drug product services and enables STA to advance new chemical entities from preclinical stage to new drug application (NDA) and to market.

    Growth in the Cell Therapy arena has also prompted capability expansions. In June, Lonza acquired PharmaCell B.V., a cell and gene contract manufacturer in Europe with employees in Maastricht and Geleen (NL). In 2016 PharmaCell had sales of €11 million.

    PharmaCell was primarily selected due to its core expertise in autologous cell and gene therapy manufacturing, which includes experience with two commercial advanced therapy medicinal products (ATMPs)-licensed products. Autologous therapies use a patient’s own cells.

    Established in 2005 when cell manufacturing was still in its infancy, PharmaCell has since been the manufacturer of the only two European-approved commercial cell therapy products. PharmaCell has more than 6,000 square meters of GMP clean rooms, QC and other support spaces.

    In August, the FDA approved the first cell therapy, Novartis’ chimeric antigen receptor T cell (CAR-T) therapy, Kymriah for the treatment of B-cell precursor acute lymphoblastic leukemia (ALL). It is the first FDA-approved CAR-T immunotherapy, which uses specifically developed Cell Therapy Systems (CTS) Dynabeads technology, part of Thermo Fisher’s Cell Therapy Systems (CTS) portfolio. The magnetic beads isolate, activate and expand T cells that have been genetically engineered to recognize and fight cancer cells in each individual patient.

    In cell therapy manufacturing, CTS Dynabeads CD3/CD28 beads deliver a scalable platform that help to streamline production with high reproducibility. Dynabeads products are for research use only or for the manufacturing of cell-, gene- or tissue-based products.

    These highly sophisticated therapies will increasingly require service providers to have equally advanced capabilities. We can expect to see more M&As drawing on the expertise of successful CMO/CDMOS. 
    Related Searches
    • Solid Dosage
    • CMO
    • Development
    • acquisition
    Suggested For You
    LSNE Expands Fill Finish and Lyophilization Ops LSNE Expands Fill Finish and Lyophilization Ops
    Drug Product Development, Manufacturing, and Packaging Drug Product Development, Manufacturing, and Packaging
    Irisys Receives NIH Contract for the Formulation of Drinabant Irisys Receives NIH Contract for the Formulation of Drinabant
    AGC Biologics Manufactures Orchard Therapeutics AGC Biologics Manufactures Orchard Therapeutics' Libmeldy
    Ajinomoto Bio-Pharma and Revance Therapeutics Partner Ajinomoto Bio-Pharma and Revance Therapeutics Partner
    Lonza Expands Conjugation Facility in Visp Lonza Expands Conjugation Facility in Visp
    Thermo Fisher Scientific Further Expands Global Footprint Thermo Fisher Scientific Further Expands Global Footprint
    Logistics4Pharma Facility Passes Inspection Logistics4Pharma Facility Passes Inspection
    Tubulis, WuXi Biologics and WuXi STA Form Strategic Pact Tubulis, WuXi Biologics and WuXi STA Form Strategic Pact
    CDMO Stelis Continues Expansion CDMO Stelis Continues Expansion
    Recipharm Inks Covid-19 Vax Pact with Moderna Recipharm Inks Covid-19 Vax Pact with Moderna
    Lonza Expands Development, Mfg. Capabilities at Bend Site Lonza Expands Development, Mfg. Capabilities at Bend Site
    CordenPharma Colorado Increases US Peptide Manufacturing Capacity CordenPharma Colorado Increases US Peptide Manufacturing Capacity
    Lonza Expands HPAPI Capabilities Lonza Expands HPAPI Capabilities
    Stelis BioSource Continues Facility Investment Stelis BioSource Continues Facility Investment

    Related Features

    • Excipients
      Bye-Bye China?

      Bye-Bye China?

      Instead of closing its doors on China, Western pharma industry needs to take a balanced approach and perform proper due diligence based on objective criteria.
      Michele Jermini and Enrico Polastro 11.17.20

    • Clinical Trials | Information Technology | R&D
      Decentralized Trials Fuel AI Revolution in Clinical Research

      Decentralized Trials Fuel AI Revolution in Clinical Research

      The life sciences industry is giving clinical a full makeover, dramatically improving how new therapeutics are developed.
      Nick Moss, Vice President of Analytics and Machine Learning, Medable 11.17.20

    • Drug Delivery | Injectables
      Self-Medication: Flexibility for Patients and Drug Manufacturers

      Self-Medication: Flexibility for Patients and Drug Manufacturers

      Bringing together self-medication with auto-injectors and sustainable secondary packaging.
      Matthias Heinrichs, Head of Product Management and Project Engineering, Syntegon Technology 11.17.20


    • The Single-Use Mixing Landscape: Evaluating Your Options

      The Single-Use Mixing Landscape: Evaluating Your Options

      Adoption of single-use technologies has increased markedly in recent years and will continue to grow.
      Mark A. Sitcoske, Founder & CEO, High Purity New England 11.17.20

    • DCAT President Talks COVID-19, Drug Manufacturing and Innovation

      DCAT President Talks COVID-19, Drug Manufacturing and Innovation

      Lonza’s Director of Commercial Development, Sean Diver, was recently named President of DCAT.
      Tim Wright, Editor, Contract Pharma 11.17.20

    • Biologics, Proteins, Vaccines | Biosimilars | Drug Development
      Biopharma Contract Manufacturing: Robust Growth Ahead

      Biopharma Contract Manufacturing: Robust Growth Ahead

      The biopharmaceutical contract manufacturing market is projected to reach $6.3 billion in 2020, and it will continue to grow over the next five years.
      William Downey, HighTech Business Decisions 11.17.20


    • Injectables
      Catering for the Complex

      Catering for the Complex

      The rapidly changing landscape of pharmaceutical packaging.
      Marcelo Cruz, Director Business Development and Marketing, Tjoapack 11.17.20

    • Cold Chain Management | Supply Chain
      Cold Chain Trends

      Cold Chain Trends

      There is a growing need for convenience through Direct-to-Patient and Direct-from-Patient services in clinical trials.
      Vince Paolizzi, Director of NanoCool Sales, Pelican BioThermal 11.17.20

    • Biologics, Proteins, Vaccines | Inspections | Supply Chain
      Inspecting the Unexpected

      Inspecting the Unexpected

      Preparing quality control processes for COVID-19 vaccine candidates.
      Dr. Andrea Sardella and Raffaele Pace, Stevanato Group 11.17.20


    • Scale-up/Technology Transfer
      Ensuring Quality During the Transfer and Scale Up of Rx Drugs

      Ensuring Quality During the Transfer and Scale Up of Rx Drugs

      Defining the key parameters and considerations for a successful technology transfer.
      Tom Chang, President, Bora Pharmaceutical Laboratory Co. Ltd. 11.17.20

    • Scale-up/Technology Transfer
      Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up

      Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up

      Identifying, assessing and mitigating threats at every stage of the development pipeline.
      Joe Willmot, Application Leader, H.E.L Group 11.17.20

    • Clinical Trials | Information Technology
      The Role of Electronic Monitoring in Maintaining Medication Adherence

      The Role of Electronic Monitoring in Maintaining Medication Adherence

      Digital solutions offer hope to get patients to take their medications properly.
      Bernard Vrijens, Scientific Lead, AARDEX Group 10.14.20


    • APIs
      Understanding the Importance of Crystallization Processes

      Understanding the Importance of Crystallization Processes

      Crystallization is a crucial aspect of a molecule’s development and can be used to avoid unnecessary cost, risk and development delays.
      Dr. Craig Callahan, Project Scientist, Cambrex Edinburgh 10.14.20

    • Capsules | Solid Dosage/Creams/Ointments
      Capsule Technology Trends

      Capsule Technology Trends

      A look at the capsule market with a particular focus on the factors driving increased demand in non-gelatin-based formulations.
      Julien Lamps, Product Manager, Lonza 10.14.20

    • Aseptic Processing | Fill/Finish
      A Holistic Cleanroom Concept: Higher Quality and Greater Flexibility

      A Holistic Cleanroom Concept: Higher Quality and Greater Flexibility

      Overcoming today’s aseptic fill-and-finish process challenges.
      Ute Schleyer, Project Manager, Site & Plant Development, Vetter 10.14.20

    Trending
    • Integrated Continuous Manufacturing ICM
    • Humanigen, Emergent Enter Covid-19 Partnership
    • Samsung Bioepis Opens New Headquarters
    • CDMO Northway Biotech Expands In U.S.
    • CONTINUUS Awarded $69.3M DoD Grant
    Breaking News
    • Civica to Build an Essential Medicines Manufacturing Facility in Virginia
    • Humanigen, Emergent Enter Covid-19 Partnership
    • Samsung Bioepis Opens New Headquarters
    • Pfizer, BioNTech Enter Vax Pact with COVAX
    • FDA Approves Janssen’s CABENUVA
    View Breaking News >
    CURRENT ISSUE

    November/December 2020

    • Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up
    • Ensuring Quality During the Transfer and Scale Up of Rx Drugs
    • Inspecting the Unexpected
    • Cold Chain Trends
    • Catering for the Complex
    • Biopharma Contract Manufacturing: Robust Growth Ahead
    • DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    • The Single-Use Mixing Landscape: Evaluating Your Options
    • Self-Medication: Flexibility for Patients and Drug Manufacturers
    • Decentralized Trials Fuel AI Revolution in Clinical Research
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Clinical Evidence Suggests Potential Oral Benefits for Curcumin Extract
    Oleic Acid Possibly Implicated in MS Pathology
    NIH Study Compares Low-Fat, Plant-Based to Low-Carb, Animal-Based Diet
    Coatings World

    Latest Breaking News From Coatings World

    APV Engineered Coatings Reflects on 2020
    LINE-X Launches Dealer Program with International Truck
    BCF CEO to Chair Royal Society of Chemistry Surface Coatings Interest Group
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Alleviant's Transcatheter Tech Obtains Breakthrough Status
    Signia Appoints New President
    At-Home COVID-19 Test Kits Boosts Disease Monitoring Capabilities
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Civica to Build an Essential Medicines Manufacturing Facility in Virginia
    Humanigen, Emergent Enter Covid-19 Partnership
    Samsung Bioepis Opens New Headquarters
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Fitglow Beauty Wins Big at Annual Dirty Thinker’s Choice Awards
    e.l.f. Cosmetics Unveils Mint Melt Collection
    Estée Lauder Companies Updates Supply Chain Leadership
    Happi

    Latest Breaking News From Happi

    Some Good News at Inter Parfums
    Professional Beauty Association Names New Executive Director
    Curcumin's Role in Oral Care
    Ink World

    Latest Breaking News From Ink World

    Paragon Expands Direct Mail Capabilities with Ricoh Pro VC70000
    BOBST Demonstrates Future of Flexible Packaging Production at Virtual Open House
    Morancé Soudure France Adds Comexi F2 MC 10-color Flexo Press
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    VPF launches deep-freeze adhesive
    ProMach strengthens flexible packaging business
    Gallus planning virtual event for March
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Kimberly-Clark Releases Q4, Full Year Results
    Freudenberg to Establish Apparel Interlining Competence Centers
    Minet Adds Spunlace Line in Romania
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    First Patient Implanted With NEXXT MATRIXX SA Cervical Turn-Lock System
    Cretex Companies CEO Steps Down
    Conformis Enters Development & Supply Agreement with SITES Medical
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    First Solar Signs Definitive Agreement to Sell US Development Platform to Leeward
    Imec Technology Taking Off to Space
    North American Semiconductor Equipment Industry Posts December 2020 Billings

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login